

ziprasidone to end January 2009

				Case Group	Death Outcomes	Sole
Case Count				104	0	84
Medicine	Reaction Count	Cardiac disorders	Arrhythmia	1	0	1
			Bradycardia	1	0	0
			Tachycardia	1	0	0
			Atrial fibrillation	3	0	3
			Ventricular arrhythmia	1	0	1
			Ventricular tachycardia	1	0	1
			Cyanosis	2	0	1
			Palpitations	2	0	2
			Acute myocardial infarction	1	0	0
			Arteriospasm coronary	1	0	0
			Myocardial infarction	1	0	1
			Cardiogenic shock	1	0	0
			Cardiac disorders	16	0	10
			Ear and labyrinth disorders	Tinnitus	1	0
		Ear and labyrinth disorders		1	0	0
		Endocrine disorders	Hyperprolactinaemia	1	0	1
			Inappropriate antidiuretic hormone secretion	1	0	0
			Endocrine disorders	2	0	1
		Eye disorders	Excessive eye blinking	1	0	1
			Gaze palsy	1	0	1
			Oculogyric crisis	2	0	2
			Asthenopia	1	0	1
			Photophobia	1	0	1
			Eye disorders	6	0	6
		Gastrointestinal disorders	Diarrhoea	3	0	3
			Dyspepsia	1	0	0
			Abdominal pain	1	0	1
			Dysphagia	2	0	2
			Nausea	6	0	5
			Vomiting	8	0	5
			Dry mouth	1	0	1
			Swollen tongue	1	0	1
			Tongue oedema	1	0	1
			Gastrointestinal disorders	24	0	19
		General disorders and administration site conditions	Pyrexia	3	0	2
			Asthenia	1	0	1
			Fatigue	4	0	2
Malaise	5		0	4		
Gait disturbance	3		0	3		
Apparent death	1		0	1		
Influenza like illness	1		0	1		

ziprasidone to end January 2009

			Case Group	Death Outcomes	Sole		
Medicine	Reaction Count	General disorders and administration site conditions	Face oedema	1	0	1	
			Oedema peripheral	1	0	1	
			Discomfort	1	0	1	
			Drug ineffective	3	0	3	
			Drug withdrawal syndrome	2	0	2	
			General disorders and administration site conditions	26	0	22	
		Immune system disorders	Hypersensitivity	1	0	1	
			Anaphylactic reaction	1	0	1	
			Immune system disorders	2	0	2	
		Injury, poisoning and procedural complications	Subdural haematoma	1	0	0	
			Fall	1	0	0	
			Injury, poisoning and procedural complications	2	0	0	
		Investigations	Electrocardiogram QT interval abnormal	1	0	1	
			Electrocardiogram QT prolonged	12	0	9	
			Electrocardiogram abnormal	1	0	0	
			Heart rate decreased	1	0	1	
			Blood pressure decreased	1	0	1	
			Blood creatine phosphokinase increased	1	0	0	
			Neutrophil count decreased	1	0	1	
			Alanine aminotransferase increased	1	0	1	
			Gamma-glutamyltransferase increased	1	0	1	
			Blood test abnormal	1	0	1	
			Quality of life decreased	1	0	1	
			Blood glucose increased	1	0	1	
			Weight decreased	1	0	1	
			Weight increased	1	0	0	
			Drug level changed	1	0	0	
			Investigations	26	0	19	
			Metabolism and nutrition disorders	Hyperkalaemia	1	0	1
				Hyponatraemia	1	0	0
		Dehydration		1	0	1	
		Hyperglycaemia		2	0	1	
		Metabolism and nutrition disorders		5	0	3	
		Musculoskeletal and connective tissue disorders	Muscle spasms	2	0	0	
			Muscle tightness	1	0	1	
			Muscle twitching	4	0	4	
			Torticollis	1	0	1	
			Trismus	2	0	2	
			Musculoskeletal stiffness	4	0	3	

ziprasidone to end January 2009

Medicine	Reaction Count		Case Group	Death Outcomes	Sole	
		Musculoskeletal and connective tissue disorders	Back pain	1	0	0
			Flank pain	1	0	0
			Musculoskeletal and connective tissue disorders	16	0	11
		Nervous system disorders	Transient ischaemic attack	1	0	0
			Headache	3	0	3
			Disturbance in attention	1	0	0
			Akathisia	10	0	9
			Dyskinesia	5	0	3
			Extrapyramidal disorder	4	0	3
			Psychomotor hyperactivity	1	0	1
			Tardive dyskinesia	6	0	5
			Dystonia	8	0	8
			Cogwheel rigidity	3	0	2
			Parkinsonian gait	1	0	1
			Parkinsonism	2	0	2
			Tremor	9	0	5
			Hyperreflexia	1	0	0
			Balance disorder	1	0	1
			Diabetic hyperosmolar coma	1	0	0
			Loss of consciousness	3	0	3
			Sedation	2	0	2
			Somnolence	1	0	1
			Syncope	6	0	6
			Clonus	2	0	1
			Dizziness	7	0	4
			Myoclonus	1	0	0
			Presyncope	1	0	0
			Paraesthesia	1	0	1
			Hypoaesthesia	1	0	1
			Dysarthria	4	0	3
			Speech disorder	2	0	1
			Neuroleptic malignant syndrome	3	0	1
			Serotonin syndrome	3	0	2
		Grand mal convulsion	1	0	0	
Convulsion	3	0	1			
Nervous system disorders	98	0	70			
Psychiatric disorders	Agitation	4	0	2		
	Anxiety	4	0	3		
	Restlessness	4	0	2		
	Tic	1	0	1		
	Dysphemia	1	0	0		
	Confusional state	2	0	1		

ziprasidone to end January 2009

			Case Group	Death Outcomes	Sole	
Medicine	Reaction Count	Psychiatric disorders	Depression	1	0	0
			Depressed mood	1	0	0
			Delusion	1	0	1
			Hallucination	1	0	1
			Hallucination, auditory	1	0	0
			Hallucination, visual	1	0	1
			Hypomania	2	0	2
			Mania	2	0	1
			Flat affect	2	0	2
			Emotional disorder	1	0	0
			Aggression	2	0	1
			Psychiatric decompensation	1	0	1
			Nicotine dependence	1	0	0
			Acute psychosis	1	0	1
			Psychotic disorder	4	0	2
			Schizophrenia	2	0	2
			Insomnia	6	0	3
			Nightmare	2	0	0
			Sleep disorder	1	0	0
			Suicidal ideation	1	0	0
		Psychiatric disorders	50	0	27	
		Renal and urinary disorders	Nephrogenic diabetes insipidus	1	0	0
			Renal and urinary disorders	1	0	0
		Reproductive system and breast disorders	Breast cyst	1	0	1
			Breast mass	1	0	1
			Gynaecomastia	1	0	1
			Breast engorgement	1	0	1
			Breast pain	2	0	2
			Galactorrhoea	1	0	1
			Menstruation irregular	1	0	1
			Reproductive system and breast disorders	8	0	8
		Respiratory, thoracic and mediastinal disorders	Dyspnoea	2	0	2
			Respiratory failure	1	0	0
			Throat tightness	1	0	1
			Pharyngeal oedema	1	0	1
			Respiratory, thoracic and mediastinal disorders	5	0	4
		Skin and subcutaneous tissue disorders	Stevens-Johnson syndrome	1	0	1
			Skin exfoliation	1	0	1
			Pruritus	3	0	2
			Rash	1	0	1
			Rash maculo-papular	1	0	0

ziprasidone to end January 2009

				Case Group	Death Outcomes	Sole		
Medicine	Reaction Count	Skin and subcutaneous tissue disorders	Acne	2	0	2		
			Alopecia	2	0	2		
			Hyperhidrosis	2	0	0		
			Ecchymosis	1	0	1		
			Skin and subcutaneous tissue disorders	14	0	10		
		Social circumstances	Family stress	1	0	1		
			Social circumstances	1	0	1		
		Surgical and medical procedures	Therapy regimen changed	2	0	1		
			Surgical and medical procedures	2	0	1		
		Vascular disorders	Orthostatic hypotension	1	0	1		
			Cardiovascular insufficiency	1	0	0		
			Vein pain	1	0	1		
			Flushing	1	0	1		
			Pallor	1	0	1		
			Vascular disorders	5	0	4		
		Reaction				310	0	218